Prevalence of uncoupling protein one genetic polymorphisms and their relationship with cardiovascular and metabolic health - Dinas, Petros C.; Nintou, Eleni; Vliora, Maria; Sakellariou, Paraskevi; Pravednikova, Anna E.; Witkowicz, Agata; Kachaev, Zaur M.; Kerchev, Victor V.; Larina, Svetlana N.; Cotton, James; Kowalska, Anna; Gkiata, Paraskevi; et al. (medRxiv, 2021)
The contribution of UCP1 single nucleotide polymorphisms (SNPs) to susceptibility for cardiometabolic pathologies (CMP) and their involvement in specific risk factors for these conditions varies across populations. We tested whether UCP1 SNPs A-3826G, A-1766G, Ala64Thr and A-112C are associated with the most common CMP (cardiovascular disease, hypertension, metabolic syndrome, and type-2 diabetes) and CMP risk factors. This case-control study included blood sample collection from 2,283 Caucasians (1,139 healthy; 1,144 CMP) across Armenia, Greece, Poland, Russia and United Kingdom for genotyping of the above-mentioned SNPs. We extended the results via a systematic review and meta-analysis, covering PubMed, Embase, and Cochrane Library databases. In Armenia the GA genotype and A allele of Ala64Thr were associated with ∼2-fold higher risk for CMP compared to the GG genotype or G allele, respectively (p<0.05). In Greece, A allele of Ala64Thr SNP decreased the risk of CMP by 39%. Healthy individuals with A-3826G GG genotype and carriers of mutant allele of A-112C and Ala64Thr had higher body mass index compared to those carrying other genotypes. In healthy Polish, higher waist-to-hip ratio (WHR) was observed in heterozygotes A-3826G compared to AA homozygotes. Heterozygosity of the A-112C and Ala64Thr SNPs was related to lower WHR in CMP individuals compared to wild type homozygotes (p<0.05). Meta-analysis in case-control studies showed no statistically significant odds ratios in different alleles across the four studied SNPs (p>0.05). Thus, we conclude that the studied SNPs could be associated with the most common CMP and their risk factors in some populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe case-control study was supported by funding from the European Union 7th Framework Program (FP7-PEOPLE-2013-IRSES Grant No. 319010; U-GENE project). The case-control study also received funding by the Russian Foundation for Basic Research (grant 19-34-51003). The Polish research center has received additional funding for the case-control study from the Polish Ministry of Science and Higher Education 2016-2017 international project co-financed W15/7.PR/2016Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This multicenter, multinational study conducted across Armenia, Greece, Poland, Russia, and United Kingdom, received approval from the relevant Bioethics Review Board in each country: 1.Armenia: Institute of Molecular Biology, National Academy of Sciences of Republic of Armenia, ref. No IRB/IEC: IRB00004079, (IORG 0003427)/3-7-2012; 2.Greece: Department of Physical Education and Sport Science, University of Thessaly, ref. No 610/9-7-2012. 3.Poland: Local Research Bioethics Committee, University of Medical Sciences, Poznan, ref. No KB 215/13 revised KB 85/16; 4.Russia: Institute of Gene Biology, Russian Academy of Sciences, ref. no 12318-308/ 6-7-2012; 5.United Kingdom: National Health Services/Manchester East Research Ethics Committee, ref. No 15/NW/0874/12-1-2016. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=132376